New drug combo targets rare, aggressive lung cancer in early trial
NCT ID NCT07200947
First seen Nov 01, 2025 · Last updated May 02, 2026 · Updated 21 times
Summary
This study tests a new two-in-one immunotherapy drug (iparomlimab and tuvonralimab) combined with standard chemotherapy as a first treatment for people with a specific, hard-to-treat type of advanced lung cancer (SMARCA4-deficient NSCLC). The goal is to see if this combination can shrink tumors or delay cancer growth. About 28 participants will receive the treatment, and researchers will monitor safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.